GREGORY JULIA P

SEC source: 0001226675-26-000006 · wk-form4_1792008695.xml · derivative · entry 3

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,583 shares

Expires 2029-12-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vested as to 1/48 of the total shares monthly beginning September 12, 2019 until the option was fully vested on August 12, 2023.

SEC source: 0001226675-26-000006 · wk-form4_1792008695.xml · nonDerivative · entry 2

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,750

F1 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $23.34 and the highest price at which shares were sold was $23.62. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

SEC source: 0001226675-26-000006 · wk-form4_1792008695.xml · nonDerivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001226675-26-000004 · wk-form4_1778881038.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,250

Underlying: Common Stock · 31,250 shares

Expires 2036-05-14

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

SEC source: 0001226675-26-000002 · wk-form4_1777593998.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,693

Underlying: Common Shares · 68,693 shares

Expires 2036-04-28

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001226675-25-000004 · wk-form4_1758149885.xml · derivative · entry 2

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,583

Underlying: Common Stock · 10,750 shares

Expires 2029-12-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock option vested as to 1/48 of the total shares monthly beginning September 12, 2019, and was vested in full on August 12, 2023.

SEC source: 0001226675-25-000004 · wk-form4_1758149885.xml · nonDerivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001549595-25-000081 · wk-form4_1747690396.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-05-18

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

SEC source: 0001935979-25-000043 · wk-form4_1746652387.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,716

Underlying: Common Shares · 31,716 shares

Expires 2035-05-05

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2026 or (b) the date of the 2026 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001549595-24-000067 · wk-form4_1716247538.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-05-19

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 20, 2025, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

SEC source: 0001562180-24-003753 · primarydocument.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,592

Underlying: Common Shares · 16,592 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-027505 · doc4.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2033-05-03

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 4, 2024, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

SEC source: 0001562180-23-003944 · primarydocument.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,906

Underlying: Common Shares · 52,906 shares

Expires 2033-05-02

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 2, 2024 or (b) the date of the 2024 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001562180-22-007336 · primarydocument.xml · nonDerivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,665

F1 · shares: Represents common shares acquired in an underwritten public offering.

SEC source: 0001562180-22-006957 · primarydocument.xml · derivative · entry 4

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 18,000 shares

Expires 2029-05-20

F2 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

SEC source: 0001562180-22-006957 · primarydocument.xml · derivative · entry 3

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 18,000 shares

Expires 2030-04-29

F2 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

SEC source: 0001562180-22-006957 · primarydocument.xml · derivative · entry 2

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 11,996 shares

Expires 2031-05-05

F2 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

SEC source: 0001562180-22-006957 · primarydocument.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 8,239 shares

Expires 2032-04-28

F1 · derivative.exercise_price: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F2 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

SEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 14

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Shares · 125,000 shares

Expires 2032-10-04

F3 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 13

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 9,000 shares

Expires 2029-05-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

SEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 12

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 9,000 shares

Expires 2030-04-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

SEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 11

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 5,998 shares

Expires 2031-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

SEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 10

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 4,119 shares

Expires 2032-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

SEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 9

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Shares · 9,000 shares

Expires 2029-05-20

F2 · derivative.exercise_price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · shares: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

SEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 8

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Shares · 9,000 shares

Expires 2030-04-29

F2 · derivative.exercise_price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · shares: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

SEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 7

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,998

Underlying: Common Shares · 5,998 shares

Expires 2031-05-05

F2 · derivative.exercise_price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · shares: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

SEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 6

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,119

Underlying: Common Shares · 4,119 shares

Expires 2032-04-28

F2 · derivative.exercise_price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · shares: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement

SEC source: 0001562180-22-007079 · primarydocument.xml · nonDerivative · entry 5

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,142

F1 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options.

SEC source: 0001562180-22-007079 · primarydocument.xml · nonDerivative · entry 4

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,117

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-22-007079 · primarydocument.xml · nonDerivative · entry 3

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,117

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-22-007079 · primarydocument.xml · nonDerivative · entry 2

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,117

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-22-007079 · primarydocument.xml · nonDerivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,119

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-027660 · doc4.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-05-04

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2023, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

SEC source: 0001562180-22-003587 · primarydocument.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,239

Underlying: Common Shares · 8,239 shares

Expires 2032-04-27

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2023 or (b) the date of the 2023 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001562180-21-007867 · primarydocument.xml · derivative · entry 3

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 12,000 shares

Expires 2027-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: This option grant was made pursuant to the Issuer's non-employee director compensation policy. The option, representing a right to purchase a total of 36,000 shares, was granted on August 2, 2017, and vested in three equal installments on August 2, 2018, 2019 and 2020.

SEC source: 0001562180-21-007867 · primarydocument.xml · nonDerivative · entry 2

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This exercise and sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001562180-21-007867 · primarydocument.xml · nonDerivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001209191-21-035536 · doc4.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2031-05-05

F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2022, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

SEC source: 0001562180-21-003337 · primarydocument.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,996

Underlying: Common Shares · 11,996 shares

Expires 2031-05-04

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2022 or (b) the date of the 2022 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001562180-21-001149 · primarydocument.xml · derivative · entry 4

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 18,000 shares

Expires 2028-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-21-001149 · primarydocument.xml · nonDerivative · entry 3

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.1996 - $72.9850, inclusive.

SEC source: 0001562180-21-001149 · primarydocument.xml · nonDerivative · entry 2

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,600

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.73 - $71.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

SEC source: 0001562180-21-001149 · primarydocument.xml · nonDerivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-20-003257 · primarydocument.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Shares · 18,000 shares

Expires 2030-04-29

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2021 or (b) the date of the 2021 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001689813-19-000095 · wf-form4_157447619674899.xml · derivative · entry 3

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Shares · 12,000 shares

Expires 2027-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · derivative.exercise_date: This option grant was made pursuant to the Issuer's non-employee director compensation policy. The option, representing a right to purchase a total of 36,000 shares was granted on August 2, 2017, vesting in three equal installments on August 2, 2018, 2019 and 2020, subject to the Reporting Person's continuous service with the Issuer at each vesting date. The Reporting Person previously exercised the option with respect to 12,000 shares on February 21, 2019.

SEC source: 0001689813-19-000095 · wf-form4_157447619674899.xml · nonDerivative · entry 2

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.01 - $55.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.

SEC source: 0001689813-19-000095 · wf-form4_157447619674899.xml · nonDerivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001209191-19-032472 · doc4.xml · derivative · entry 1

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Shares · 18,000 shares

Expires 2029-05-20

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 21, 2020 or (b) the date of the 2020 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-19-012998 · doc4.xml · derivative · entry 3

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Shares · 12,000 shares

Expires 2027-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and the subsequent sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 22, 2019.

F3 · derivative.exercise_date: This option grant was made pursuant to the Issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on August 2, 2018, 2019 and 2020, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0001209191-19-012998 · doc4.xml · nonDerivative · entry 2

GREGORY JULIA P · CIK 0001226675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This exercise and the subsequent sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 22, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.20 - $44.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.